Adlai Nortye, a China-based clinical-stage biopharmaceutical firm that develops immuno-oncology medicines, on Monday announced the completion of nearly $100 million in a Series C round of financing.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
